Vascular Diseases
Affect Millions;
Innovative Treatments
Are Still Needed

Introducing BioGenCell’s revolutionary cell therapy, harnessing cell therapy to provide a simple and accessible solution to the needs of patients and the healthcare community.

technology

Existing Treatments Still Not Able to Address:

The Major Health Concerns

Major Health Concerns

Vascular diseases can cause conditions such as peripheral vascular disease, heart disease, stroke, and blindness, and account for 25% of global death cases.

The High Treatments Costs

High Treatments Costs

The cost of treating microvascular diseases places a significant financial burden on patients, institutions and payers, amounting to billions of dollars each year.

No-Option Patients

Despite major advancements in science and medicine, healthcare providers are still looking for solutions for patients who don’t respond to traditional treatments.

Personalized Treatments in 3 Steps

In three steps, we make personalized cell therapy available for everyone.
We do so by mimicking, externally, the natural processes of the body enabling cells to flourish outside
their natural environment.

Blood collection

Blood collection

Processing

Processing

Treatment

Treatment

The BioGenCell TRACT Leap

Our TRACT platform uses innovative bio technology to turn a patients own blood into a mass-produced treatment. BioGenCell is able to produce the treatment in one day, and apply it in a single appointment.
1 Day

Production

Single

Treatment

Lasting

Lasting

Effect 

Clinical Advantages:
Safe and Accessible Treatments

The Science Behind BioGenCell

We harness the alternative activation pathways to modulate stem/progenitor cell-specific activity

Power of
the Immune
System

biogencell trial

Power of
Stem Cells

biogencell trial

Tailored
Multifunctional
Therapeutic
Cells

biogencell trial

Selected references: Fernandez 2001, Riboldi 2005, Tang 2006, Sozzani 2007, Porat 2014, Niven 2021

Lead Product Line
BGC10X

This Product line implements the company’s technology for treating blood vessel insufficiency that causes multiple organ failure in the elderly and diabetic patient populations.

Join our Clinical Trial
for BGC101

This Product line implements the company’s technology for treating blood vessel insufficiency that causes multiple organ failure in the elderly and diabetic patient populations.

Expanding the Possibilities

An Horizon of New Hope for Patients

Starting with BGC10X for Microvascular Diseases, BioGenCell’s pipeline shows great potential for treating a range of degenerative diseases. Our cutting-edge research and development team is working tirelessly to bring more innovative therapies to market.

We may use cookies to enhance your browsing experience, and analyze usage in the Website.